Chlorinated tetralin compounds and pharmaceutical compositions
US-2023091097-A1 · Mar 23, 2023 · US
Chlorinated tetralin compounds and pharmaceutical compositions
US11844780B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11844780-B2 |
| Application number | US-202318301742-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 17, 2023 |
| Priority date | Sep 8, 2021 |
| Publication date | Dec 19, 2023 |
| Grant date | Dec 19, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a desmoid tumor in a patient in need thereof comprising orally administering to the patient a pharmaceutical composition comprising a compound of Formula IB or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 , wherein the compound of Formula IB or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 300 μg. 3. The method of claim 1 , wherein the compound of Formula IB or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 250 μg. 4. The method of claim 1 , wherein the compound of Formula IB or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 150 μg. 5. The method of claim 1 , wherein the compound of Formula IB or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 100 μg. 6. The method of claim 1 , wherein the compound of Formula IB or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 50 μg. 7. The method of claim 1 , wherein the pharmaceutical composition further comprises nirogacestat or a pharmaceutically acceptable salt thereof. 8. The method of claim 7 , wherein the compound of Formula IB or pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 300 μg. 9. The method of claim 8 , wherein the pharmaceutical composition comprises 50 mg nirogacestat or a pharmaceutically acceptable salt thereof. 10. The method of claim 7 , wherein the compound of Formula IB or pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 250 μg. 11. The method of claim 10 , wherein the pharmaceutical composition comprises 50 mg nirogacestat or a pharmaceutically acceptable salt thereof. 12. The method of claim 7 , wherein the compound of Formula IB or pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 150 μg. 13. The method of claim 12 , wherein the pharmaceutical composition comprises 50 mg nirogacestat or a pharmaceutically acceptable salt thereof. 14. The method of claim 7 , wherein the compounds of Formula IB or pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 100 μg. 15. The method of claim 14 , wherein the pharmaceutical composition comprises 50 mg nirogacestat or a pharmaceutically acceptable salt thereof. 16. The method of claim 7 , wherein the compound of Formula IB or pharmaceutically acceptable salt thereof in the pharmaceutical composition is present in an amount of about 1 μg to about 50 μg. 17. The method of claim 16 , wherein the pharmaceutical composition comprises 50 mg nirogacestat or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title
Antineoplastic agents · CPC title
- A61K31/417Primary
Imidazole-alkylamines, e.g. histamine, phentolamine · CPC title
- C07D233/88Primary
Nitrogen atoms, e.g. allantoin · CPC title
Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11844780B2 cover?
- The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.
- Who is the assignee on this patent?
- Springworks Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/417. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).